← FDA DRUG APPROVALS

FDA ANDA · ANDA080408

LIDOCAINE HYDROCHLORIDE

Sponsor: HOSPIRA

APPLICATION
ANDA080408
TYPE
ANDA
ORIGINAL APPROVAL
1972-09-28
LATEST ACTION
2020-03-19
ROUTE
EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREEPrescription
LIDOCAINE HYDROCHLORIDE 1.5% · INJECTABLE · INJECTION
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREEPrescription
LIDOCAINE HYDROCHLORIDE 1% · INJECTABLE · INJECTION

Approval history

2020-03-19Labeling · Supplement 61 · standardAP
2020-03-19Labeling · Supplement 58 · standardAP
2010-04-16Labeling · Supplement 48AP
2002-01-02Labeling · Supplement 31AP
1997-02-24Manufacturing (CMC) · Supplement 30AP
1996-10-03Manufacturing (CMC) · Supplement 29AP
1990-09-28Labeling · Supplement 26AP
1989-06-13Manufacturing (CMC) · Supplement 27AP
1988-11-28Labeling · Supplement 25AP
1986-07-25Manufacturing (CMC) · Supplement 24AP
1985-08-09Manufacturing (CMC) · Supplement 23AP
1982-09-14Manufacturing (CMC) · Supplement 21AP
1982-09-14Manufacturing (CMC) · Supplement 20AP
1972-09-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →